The Effect of Immunized Platelet Transfusion Refractoriness on Allo-HSCT Patients with Malignant Hematological Diseases.
10.19746/j.cnki.issn.1009-2137.2021.06.040
- Author:
Yuan-Ling ZUO
1
;
Ju-Ping ZHAI
1
;
Yong LI
1
;
Min JIANG
2
;
Qing-Ya CUI
3
;
Xiao-Wen TANG
4
;
Yi-Ming ZHAO
5
;
Jian-Ming ZHANG
6
Author Information
1. Department of Blood Transfusion, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.
2. Department of Blood Transfusion, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China,E-mail: jiangmin_111@163.com.
3. Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.
4. Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China,E-mail: xwtang1020@163.com.
5. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.
6. Department of Clinical Laboratory, Suzhou Municipal Hospital, Suzhou 215002, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute;
Male;
Myelodysplastic Syndromes;
Platelet Transfusion;
Retrospective Studies
- From:
Journal of Experimental Hematology
2021;29(6):1923-1928
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the characteristics of platelet antibody in patients with hematological diseases, so as to research the effect of immunized platelet transfusion refractoriness (PTR) on the prognosis of allogeneic hematopoietic stem cell transplantation (allo-HSCT) recepients with malignant hematological diseases patients.
METHODS:The clinical data of platelet antibody positive patients tested by Capture-P in the First Affiliated Hospital of Soochow University from July 1, 2014 to July 1, 2019 were retrospectively analyzed, including sex, age, disease, platelet transfusion assessments, CD34
RESULTS:In 5 years, 913 (7.28%) hematologic patients with platelet antibody positive were identified, the detection rate of females (513 cases) were higher than males (400 cases). Among the 913 patients, the antibody positive rates of 520 patients with malignant hematological diseases (acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome) showed significantly statistical different (10.27%, 8.01%, and 7.20%) (P<0.01), and the positive rate of the acute myeloid leukemia of those patients was higher than myelodysplastic syndrome patients(α<0.0125). There were 35 cases diagnosed as immunized PTR before allo-HSCT, the platelet increments, 14 h correct count increment, progression-free survival rate and overall survival rate of those patients were significantly lower than those in negative transfusion effective patients (P<0.01), while the percentage of ABO matching was significantly higher (α<0.0125).
CONCLUSION:The positive rate of platelet antibody identification is high in females and acute myeloid leukemia patients, and immunized PTR caused by antibody is a risk factor for poor prognosis of allo-HSCT in malignant hematological disease patients.
